- Home
- CYD vs GHRS Comparison
CYD vs GHRS Comparison
Compare CYD & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYD | GHRS |
|---|---|---|
| Founded | 1951 | 2018 |
| Country | Singapore | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYD | GHRS |
|---|---|---|
| Price | $46.65 | $28.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $60.00 | $41.38 |
| AVG Volume (30 Days) | 121.5K | ★ 268.5K |
| Earning Date | 02-24-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.11 | N/A |
| Revenue Next Year | $8.67 | N/A |
| P/E Ratio | $32.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.35 | $11.32 |
| 52 Week High | $61.48 | $31.00 |
Technical Indicators
Market Signals| Indicator | CYD | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 54.15 | 57.59 |
| Support Level | $47.15 | $12.94 |
| Resistance Level | $56.55 | $28.96 |
| Average True Range (ATR) | 2.04 | 1.53 |
| MACD | 0.50 | -0.15 |
| Stochastic Oscillator | 84.66 | 45.76 |
Price Performance
Historical ComparisonAbout CYD China Yuchai International Limited
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.